Praluent (alirocumab) is a prescription medication used to lower high levels of cholesterol in the blood, particularly focusing on low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. It belongs to a class of drugs known as PCSK9 inhibitors, which work by blocking the protein PCSK9, thereby allowing the liver to remove more LDL cholesterol from the blood. Praluent is typically prescribed to individuals who have not been able to adequately lower their cholesterol levels through diet and statin therapy, and it may be particularly beneficial for those with a genetic condition leading to high cholesterol levels or individuals with established cardiovascular disease. Administered via subcutaneous injection, Praluent is part of a comprehensive treatment plan that includes diet, exercise, and statin therapy to help reduce the risk of heart attack, stroke, and certain types of heart surgery in high-risk patients.